Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company focused on developing potential best-in-class medicines for serious and rare diseases, has announced the approval of inducement grants for two new employees. The grants, approved by the Compensation Committee of the company's Board of Directors, consist of non-qualified stock options to purchase 19,500 shares of Viridian's common stock.
These grants, made on August 1, 2024, are outside the company's Amended and Restated 2016 Equity Incentive Plan but remain subject to its terms. The options have an exercise price equal to the closing price of Viridian's stock on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, contingent on continued employment.
Viridian Therapeutics (Nasdaq: VRDN), una società biofarmaceutica focalizzata sullo sviluppo di potenziali farmaci di punta per malattie gravi e rare, ha annunciato l'approvazione di concessioni di incentivazione per due nuovi dipendenti. Le concessioni, approvate dal Comitato per la Compensazione del Consiglio di Amministrazione dell'azienda, consistono in opzioni su azioni non qualificate per l'acquisto di 19.500 azioni della comune di Viridian.
Queste concessioni, effettuate il 1 agosto 2024, sono al di fuori del piano di incentivazione azionaria modificato e riformulato del 2016 dell'azienda, ma rimangono soggette ai suoi termini. Le opzioni hanno un prezzo di esercizio uguale al prezzo di chiusura delle azioni di Viridian alla data della concessione e si matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura in 36 rate mensili, contingentato sul mantenimento dell'impiego.
Viridian Therapeutics (Nasdaq: VRDN), una empresa biofarmacéutica centrada en el desarrollo de medicamentos potencialmente de clase mundial para enfermedades graves y raras, ha anunciado la aprobación de subvenciones por inducimiento para dos nuevos empleados. Las subvenciones, aprobadas por el Comité de Compensación de la Junta Directiva de la empresa, consisten en opciones sobre acciones no calificadas para comprar 19,500 acciones de las acciones comunes de Viridian.
Estas subvenciones, otorgadas el 1 de agosto de 2024, están fuera del Plan de Incentivos de Capital Modificado y Restablecido de 2016 de la empresa, pero siguen sujetas a sus términos. Las opciones tienen un precio de ejercicio igual al precio de cierre de las acciones de Viridian en la fecha de la concesión y se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose en 36 cuotas mensuales, condicionado al empleo continuo.
Viridian Therapeutics (Nasdaq: VRDN)는 심각한 희귀 질환을 위한 잠재적인 최상급 의약품 개발에 초점을 맞춘 생물약품 회사로, 두 명의 신입 직원에 대한 유인 보상 승인을 발표했습니다. 이 보상은 회사 이사회 보상위원회에서 승인했으며, 19,500주를 구매할 수 있는 비적격 주식 옵션으로 구성됩니다.
이 보상은 2024년 8월 1일에 이루어졌으며, 회사의 개정 및 재설정된 2016년 주식 인센티브 플랜의 적용을 받지 않지만, 그 조건에 여전히 따릅니다. 옵션의 행사 가격은 보상 날짜의 Viridian 주식 종가와 동일하며, 4년에 걸쳐 베스트됩니다. 첫 해에 25%가 베스트되고 나머지는 고용 지속 조건부로 36개월 분할 베스트됩니다.
Viridian Therapeutics (Nasdaq: VRDN), une entreprise biopharmaceutique axée sur le développement de médicaments potentiellement parmi les meilleurs de leur catégorie pour des maladies graves et rares, a annoncé l'approbation de subventions d'incitation pour deux nouveaux employés. Les subventions, approuvées par le Comité de Rémunération du Conseil d'Administration de la société, consistent en options d'achat d'actions non qualifiées pour l'acquisition de 19 500 actions de l'action ordinaire de Viridian.
Ces subventions, accordées le 1er août 2024, sont en dehors du Plan d'Incentive d'Actions Modifié et Révisé de 2016 de l'entreprise, mais demeurent soumises à ses conditions. Les options ont un prix d'exercice égal au prix de clôture de l'action de Viridian à la date de la subvention et deviendront acquises sur quatre ans, avec 25% acquis après un an et le reste acquis en 36 mensualités, sous réserve de l'emploi continu.
Viridian Therapeutics (Nasdaq: VRDN), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung potenziell marktführender Medikamente für schwere und seltene Erkrankungen konzentriert, hat die Genehmigung von Induktionszuschüssen für zwei neue Mitarbeiter bekanntgegeben. Die Zuschüsse, die vom Vergütungsausschuss des Vorstands der Gesellschaft genehmigt wurden, bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 19.500 Aktien des Stammkapitals von Viridian.
Diese Zuschüsse, die am 1. August 2024 gewährt wurden, liegen außerhalb des überarbeiteten und neu gefassten Aktienoptionsplans 2016 des Unternehmens, unterliegen aber weiterhin dessen Bedingungen. Die Optionen haben einen Ausübungspreis, der dem Schlusskurs der Viridian-Aktien am Gewährungstag entspricht, und werden über vier Jahre hinweg fällig, wobei 25% nach einem Jahr fällig werden und der Rest in 36 monatlichen Raten, abhängig von der fortgesetzten Anstellung.
- Viridian is attracting new talent with stock option incentives
- The company is expanding its workforce, potentially indicating growth
- None.
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for VRDN-001, including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two planned global phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807247885/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares of Viridian Therapeutics (VRDN) stock were granted as inducement options on August 1, 2024?
What is the vesting schedule for the inducement grants issued by Viridian Therapeutics (VRDN)?
How many new employees received inducement grants from Viridian Therapeutics (VRDN) on August 1, 2024?
What is the exercise price of the inducement grants issued by Viridian Therapeutics (VRDN)?
